45 GHP Q3 2024 Lupin Healthcare is a leading generic medicine supplier in the UK, providing medical institutions with high-quality generic and specialist medicines. It is a fine example of a company which operates according to its core values, delivering products with integrity, a passion for excellence, and a focus on the customer. Thanks to Lupin, patients nationwide have consistent access to vital medications which are provided affordably to their dispensing institutions. The company’s supply mission is based around delivering the best possible value to the UK, the NHS, and patients. The entrepreneurial spirit at the heart of Lupin drives its team to assess and re-assess medical needs to ensure that its products are achieving those goals. In Senior Product Manager Matthew Duggan’s words, “we pride ourselves on making a difference,” and Lupin continues to make a profound one. Atop its history with generic medicines, Lupin Healthcare is also a key player in the UK’s medical research space. Its research and development team is currently exploring opportunities to expand the company’s portfolio of respiratory medical solutions, owing to its strong focus on respiratory and neuromuscular concerns. Further developments are underway, set to bolster the UK’s supply of specialist medicines alongside Lupin’s contribution to complex generics. When the need for generic medicines arises, many suppliers are ready to meet the demand, though few are as well-suited to the task as Lupin Healthcare. Since 2009, its team has pooled efforts not just into supplying hospitals and pharmacies across the UK, but it has also been a proud, valuable partner to the NHS and undertaken groundbreaking research and development projects. Here, we explore why its latest award win, Best Generic Medicines Pharmaceutical Subsidiary 2024, is so well-earnt. A Steadily Rising Pillar of Generic Medicine Supply At 1,700 strong, the company’s global research team is steadily breaking new ground in its mission to produce specialty medications, deliverable in innovative forms, and at an affordable rate to the purchaser. Its strong focus on and commitment to the patient keeps affordability at the forefront of its goals, benefitting every member in the sales and distribution pipeline. “We are well on track to emerge as an innovation-led transnational pharmaceutical organisation providing affordable healthcare solutions with uncompromising quality. Within Europe, Nanomi, a Lupin business, leads the field in nanoparticle manufacture and complex injectable development.” As the company grows further, it seeks to form strategic partnerships to streamline operations and further increase its scope. This includes partners across co-development, inlicensing, marketing, and distribution, all of whom will be a welcome addition to Lupin’s mission. It is an exciting time for the company, and with growth on the horizon, the team looks forward to offering even more in its valuable partnership with the NHS. With a stronger network of partners, Lupin will only strengthen its lead within its respective research and product niches. With an ever-expanding portfolio of patents, medicines, and an efficient research and development pipeline, Lupin Healthcare enjoys a front-runner position within its industry. In the company’s words, “the energy and excitement of our immersion in drug development and discovery is what fuels Lupin’s journey as an innovation-lad transnational pharmaceutical powerhouse.” Pharmacies, hospitals, and patients alike benefit from its leading work and will reap the rewards of its innovation for years to come. We at Global Health and Pharma are proud to award Lupin Healthcare the title of Best Generic Medicines Pharmaceutical Subsidiary 2024. Contact: Matthew Duggan Company: Lupin Healthcare Web Address: www.lupinhealthcare.co.uk Email: [email protected] I
RkJQdWJsaXNoZXIy MTUyMDQwMA==